MAGE-A3 Immunotherapeutic Fails in Stage III Melanoma - Cancer Network

Cancer Network
MAGE-A3 Immunotherapeutic Fails in Stage III Melanoma
Cancer Network
An antigen-specific immunotherapeutic known as MAGE-A3 was no better than placebo for the adjuvant treatment of stage IIIB or IIIC melanoma, according to results of a phase III trial. Development of the agent has now been stopped. Despite recent ...